Koninklijke Philips NV vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Koninklijke Philips NV trades at $25.28 (market cap $24.24B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $38.05 (market cap $63.57B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is far larger — about 2.6× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (4.07%). Which is the better fit depends on your goals.
| PHG | RELX | |
|---|---|---|
Market Cap | $24.24B | $63.57B |
Volume | 982,766 | 1,602,093 |
Sector | Health | Industrials |
52-Week High | $32.91 | $46.80 |
52-Week Low | $23.81 | $27.73 |
Typical Hold Time | 84 Days | — |
Enterprise Value | $30.57B | $75.05B |
Dividend Yield | 4.07% | 2.49% |
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.00, up 1.05% today, with a bullish technical signal despite mixed oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.57 exceeding the $0.40 estimate. Revenue for 2025 was $17.83 billion, with a net income margin of 5.01%, showing a recovery from prior losses. Recent news highlights product launches and strategic partnerships in healthcare technology.
The outlook is cautiously optimistic, supported by earnings momentum and innovation, but risks include competitive pressures and debt levels. Analysts are mixed, with a 'Hold' consensus, while institutional buying activity indicates underlying confidence. Valuation metrics like a P/E of 19.49 suggest the stock is fairly priced relative to peers.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Trailing returns across standard periods
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →